Health Trials

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

ConditionsEndometrial CancerOvarian CancerOvarian Cancer MetastaticOvarian Cancer Metastatic RecurrentNon-squamous EGFR Wt NSCLCPlatinum Resistant Ovarian CancerPROC
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorWhitehawk Therapeutics, Inc.

About this trial

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Eligibility criteria

Qualifiers

non-squamous EGFR-Wt NSCLC

Endometrial carcinoma

Platinum Resistant Ovarian Cancer

Non-squamous EGFR-Wt NSCLC

Disqualifiers

Individual with known or suspected uncontrolled central nervous system (CNS) metastases

Individual with history of carcinomatous meningitis

Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection

Individual with evidence of corneal keratopathy or history of cornea transplant

Trial design

Treatments tested in this trial

  • HWK-007

Treatment groups

226 Participants
are divided into 5 treatment groups

Sponsors and collaborators

Whitehawk Therapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov